Episode 155: Understanding Variability in Infantile Spasms Care

Episode 155 of the NeurologyLive^® Mind Moments^® podcast is now live! Scroll down to listen or click here to subscribe on your favorite streaming service.

The Mind Moments podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis, Parkinson disease, dementia, sleep disorders, and more.

In this episode, "Understanding Variability in Infantile Spasms Care," Christina Briscoe, MD, epileptologist at Boston Children’s Hospital, discusses new multi-center findings on current treatment practices for infantile epileptic spasms syndrome (IESS). Briscoe outlines why first- and second-line therapies remain largely standardized, yet significant variability emerges once hormonal therapy and vigabatrin fail. She details the evidence gaps driving inconsistent third-line and fourth-line decision-making, including limited clinical trial data, uneven access to ketogenic diet programs and epilepsy surgery, and historically low industry investment in infant-specific trials. Additional discussion focuses on ongoing research from the Pediatric Epilepsy Research Consortium, national and global comparisons in treatment pathways, barriers to study scalability in rare pediatric epilepsies, and the practical challenges of implementing timely diagnosis and standardized care across diverse healthcare settings. Briscoe also highlights under-recognized issues such as incorporation of ketogenic diet and early surgical evaluation into treatment pathways, and emphasizes the need for broader infrastructure, funding, and multi-center collaboration to improve outcomes for children with IESS.

The stories featured in this week’s Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission
• FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy
• GLP-1 Semaglutide Fails to Outperform Placebo in Phase 3 EVOKE Trial of Alzheimer Disease

EPISODE BREAKDOWN

• 1:05 – Origins of the study, need to pursue more standardized care in IESS
• 4:40 – Reasons behind treatment variability after first and second-line options
• 8:00 – What research is needed to guide sequencing and standardize care
• 12:05 – Neurology News Minute
• 14:30 – What makes IESS studies difficult and how infrastructure can improve
• 18:50 – Lesser-discussed gaps, including ketogenic diet and surgical evaluation

Click here to subscribe to the Mind Moments podcast. Be sure to leave a rating and review for the show. Thanks for listening!

Hoping to listen on your favorite podcast app? See below:

• Click here for Apple Podcasts
• Click here for Spotify
• Click here for Google Podcasts